March 14, 2019 08:42 AM EDT
Pharma

Mer­ck notch­es fourth lung can­cer ap­proval in Eu­rope for flag­ship Keytru­da

Natalie Grover

Reporter

Mer­ck’s key­stone im­munother­a­py Keytru­da has won yet an­oth­er lung can­cer ap­proval in Eu­rope, this time as the first line of de­fense for pa­tients with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

A service from the Financial Times